Helen Knows She Can Rely on Biosimilars

Thursday December 17, 2020

Diagnosed in her late twenties with incurable stage four non-Hodgkin lymphoma, Helen, now 41 and a wife and mother of two in Florida, knows she can rely on biosimilars to help when needed, so she can live her life to the fullest.

After years of trial and error with several different treatment options that left her feeling debilitated, Helen found balance with biosimilars — safe, effective alternatives to brand-name biologics. These life-changing treatment options undergo rigorous FDA testing, review and safety monitoring, allowing patients like Helen access to cutting-edge medicines.

Helen’s biosimilar helped regenerate her white blood cell count, which is a sign of a strong immune system. She is now able to take her family to the beach and amusement parks again, or just go for long nightly walks.

In her own words, “After just two treatments of the biosimilar I started to feel like me again. I was able to go back to work and my most important roles as a mother and wife. Taking a biosimilar is easy, I just go to the doctor’s, get a shot and leave. I didn’t have any major side effects. After everything I have been through it’s wonderful. Because I have a non-curable form of non-Hodgkin lymphoma that lays dormant but will always continue to come back, I know my medication journey will be lifelong. It is nice to know that when I need a biosimilar again, it will be there for me.”

For Helen, this is a lifelong battle, but thanks to biosimilars, she can get back to living her life to the fullest and be there for her family.


About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

 

GRx+Biosims 2020

Planning + Ready: Join us November 9-11, 2020 for the premier scientific and regulatory event for the U.S. generics and biosimilars industries.

LEARN MORE

Recent Tweets